UCB Japan Obtains FDA Approval of Treatment Drug for Epilepsy Patients.
The 15- minute intravenous infusion of Keppra offers an alternative for patients who find oral administration difficult or temporarily not feasible. The drug is prescribed to adults and children four years of age and older with epilepsy.
Keppra has already been approved in March 2006 from the European Commission.
Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Aug 15, 2006|
|Previous Article:||NIAS and Sanger Institute Concludes Agreement on Pig Genome Research.|
|Next Article:||Arosystem to Release 3DCG AMD Opteron CAD/CAM.|